P-2 Microglobulin as a Prognostic Factor in Non-Hodgkin's Lymphomas
Author Information
Author(s): P.W.M. Johnson, J. Whelan, S. Longhurst, K. Stepniewska, J. Matthews, J. Amess, A. Norton, A.Z.S. Rohatiner, T.A. Lister
Primary Institution: St Bartholomew's Hospital, London, UK
Hypothesis
Can P-2 microglobulin levels in serum predict treatment outcomes in patients with high-grade non-Hodgkin's lymphoma?
Conclusion
P-2 microglobulin is an independent prognostic factor for response to treatment, duration of remission, and survival in patients with diffuse aggressive non-Hodgkin's lymphomas.
Supporting Evidence
- Patients with normal P-2 microglobulin levels had a 70% remission rate compared to 37% for those with elevated levels.
- Median duration of remission was over 6 years for patients with normal levels, compared to 19 months for those with elevated levels.
- Overall survival was significantly better in patients with normal P-2 microglobulin levels, with a median survival of over 6 years.
Takeaway
Doctors can check a protein called P-2 microglobulin in the blood to see how likely it is that a patient with a type of blood cancer will get better after treatment.
Methodology
P-2 microglobulin levels were measured in serum from 262 patients treated with chemotherapy for high-grade lymphoma over a 15-year period.
Limitations
The study was conducted at a single center, which may limit the generalizability of the findings.
Participant Demographics
Patients were adults with high-grade non-Hodgkin's lymphoma, with a median age of 55 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website